Farallon Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Farallon Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$303M	Buy	8,338,098 +1,405,000	+20%	+$62.8M	1.73%	21
2025 Q4	$323M	Buy	6,933,098 +1,163,000	+20%	+$51.8M	1.46%	25
2025 Q3	$240M	Buy	5,770,098 +1,124,000	+24%	+$35.9M	0.98%	34
2025 Q2	$134M	Buy	4,646,098 +41,000	+0.9%	+$1.27M	0.56%	42
2025 Q1	$154M	Buy	4,605,098 +530,000	+13%	+$19.8M	0.74%	41
2024 Q4	$208M	Buy	4,075,098 +2,913,098	+251%	+$163M	0.91%	38
2024 Q3	$59.4M	Buy	1,162,000 +665,000	+134%	+$34.3M	0.26%	59
2024 Q2	$22.3M	Buy	497,000 +492,000	+9,840%	+$22.7M	0.1%	71
2024 Q1	$234K	Sell	5,000 -117,904	-96%	-$4.61M	﹤0.01%	140
2023 Q4	$4.37M	Sell	122,904 -239,000	-66%	-$7.33M	0.02%	95
2023 Q3	$10.8M	Buy	+361,904	New	+$7.46M	0.05%	86
2019 Q1	–	Sell	-95,365	Closed	-$2.86M	–	98
2018 Q4	$2.86M	Sell	95,365 -46,450	-33%	-$1.31M	0.02%	92
2018 Q3	$4.06M	Buy	+141,815	New	+$4.21M	0.02%	93

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Farallon Capital Management's CRNX Position: Q1 2026 in Review

Farallon Capital Management increased its Crinetics Pharmaceuticals (CRNX) stake by 20% in Q1 2026, buying an estimated $62.8M and bringing the position to 8,338,098 shares worth $303M. The position accounts for 1.73% of the portfolio, ranked #21.

Farallon Capital Management first reported a position in CRNX in Q3 2018 and has held it in 13 quarters since. The position peaked at $323M in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Farallon Capital Management held 8,338,098 shares of Crinetics Pharmaceuticals worth $303M as of Q1 2026.
Farallon Capital Management bought 1,405,000 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $62.8M.
Crinetics Pharmaceuticals made up 1.73% of Farallon Capital Management's portfolio in Q1 2026, its #21 holding.
Farallon Capital Management first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 13 quarters since.
Farallon Capital Management's Crinetics Pharmaceuticals position peaked at $323M in Q4 2025.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.